Onward Medical Pivotal Up-LIFT data published in Nature

Onward published detailed results of its pivotal Up-LIFT trial for ARCEX in the renowned magazine Nature. The data elaborates on the previously announced 72% response rate, revealing meaningful improvements across strength, function, sensory and quality of life, and demonstrates the safety of the therapy. Importantly, responses did not plateau toward the end of the observation period, and could therefore still increase in longer-term follow-up. With anticipated FDA approval toward YE24, we reiterate our bullish stance with a € 9.3 TP and Buy rating.